The effect of CTLA-4 A49G polymorphism on rheumatoid arthritis risk: a meta-analysis

Diagnostic Pathology

Ye Li¹  Jingchen Liu¹  Fengjun Shi²  Gang Li² 

[1] Department of Spine Surgery China-Japan Union Hospital, Jilin University, Changchun 130031, China;Department of Orthopaedics, Daqing General Hospital Group Oilfield General Hospital, Daqing 163001, China

关键词: Polymorphism;    CTLA-4;    Rheumatoid arthritis;   

Others  :  1150020
DOI  :  10.1186/s13000-014-0157-0

 received in 2014-06-18, accepted in 2014-07-29,  发布年份 2014

【 摘 要 】

Background

Recently, a number of studies have been performed to explore the association between CTLA-4 A49G polymorphism and rheumatoid arthritis (RA). However, the results of previous works are still controversial and ambiguous.

Methods

In this work, we attempted to perform an updated meta-analysis of available case¿control study in order to assess the association between CTLA-4 A49G polymorphism and RA risk. We searched the various citation databases without limits on languages. Article searching was performed by screening the references of retrieved studies manually. Odds ratios (OR) and 95% confidence intervals (95% CI) were calculated to evaluate the strength of the association.

Results

We totally compiled 27 studies in 24 articles (9805 RA patients and 10691 control subjects) into our meta-analysis work. We found significant association between CTL-A4 A49G polymorphism and RA risk (GG vs. AA: OR?=?1.13, 95% CI?=?1.03¿1.23; GA vs. AA: OR?=?1.19, 95% CI?=?1.07¿1.33; GA?+?GG vs. AA: OR?=?1.18, 95% CI?=?1.07¿1.29). In the subgroup analysis by ethnicity, evidences of significantly increased risk was also found in both Asian (GG vs. AA: OR?=?1.34, 95% CI?=?1.15¿1.55; GA?+?GG vs. AA: OR?=?1.24, 95% CI?=?1.08¿1.41) and Caucasian population (GA vs. AA: OR?=?1.19, 95% CI?=?1.03¿1.37; GA?+?GG vs. AA: OR?=?1.14, 95% CI?=?1.01¿1.29). No evidence of publication bias was found in this work.

Conclusions

Our meta-analysis suggests that CTLA-4 A49G polymorphism was associated with RA risk.

Virtual Slides

The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_157 webcite

【 授权许可】

   
2014 Li et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Costenbader KH, Chang SC, Laden F, Puett R, Karlson EW: Geographic variation in rheumatoid arthritis incidence among women in the united states. Arch Intern Med 2008, 168:1664-1670.
• [2]Ramirez-Soriano A, Lao O, Soldevila M, Calafell F, Bertranpetit J, Comas D: Haplotype tagging efficiency in worldwide populations in ctla4 gene. Genes Immun 2005, 6:646-657.
• [3]Teft WA, Kirchhof MG, Madrenas J: A molecular perspective of ctla-4 function. Annu Rev Immunol 2006, 24:65-97.
• [4]Antczak A, Pastuszak-Lewandoska D, Gorski P, Domanska D, Migdalska-Sek M, Czarnecka K, Nawrot E, Kordiak J, Brzezianska E: Ctla-4 expression and polymorphisms in lung tissue of patients with diagnosed non-small-cell lung cancer. Biomed Res Int 2013, 2013:576486.
• [5]Bajor DL, Vonderheide RH: Cracking the stone: Combination vaccination and ctla-4 blockade in pancreatic cancer. J Immunother 2013, 36:362-364.
• [6]Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP, Formenti SC: Immune-mediated inhibition of metastases after treatment with local radiation and ctla-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005, 11:728-734.
• [7]Lee YH, Song GG: A meta-analysis of the association between ctla-4 +49 a/g, ?318 c/t, and il-1 polymorphisms and susceptibility to cervical cancer. Neoplasma 2014, 61:481-490.
• [8]Wada S, Jackson CM, Yoshimura K, Yen HR, Getnet D, Harris TJ, Goldberg MV, Bruno TC, Grosso JF, Durham N, Netto GJ, Pardoll DM, Drake CG: Sequencing ctla-4 blockade with cell-based immunotherapy for prostate cancer. J Transl Med 2013, 11:89. BioMed Central Full Text
• [9]Seidl C, Donner H, Fischer B, Usadel KH, Seifried E, Kaltwasser JP, Badenhoop K: Ctla4 codon 17 dimorphism in patients with rheumatoid arthritis. Tissue Antigens 1998, 51:62-66.
• [10]Matsushita M, Tsuchiya N, Shiota M, Komata T, Matsuta K, Zama K, Oka T, Juji T, Yamane A, Tokunaga K: Lack of a strong association of ctla-4 exon 1 polymorphism with the susceptibility to rheumatoid arthritis and systemic lupus erythematosus in japanese: An association study using a novel variation screening method. Tissue Antigens 1999, 54:578-584.
• [11]Gonzalez-Escribano MF, Rodriguez R, Valenzuela A, Garcia A, Garcia-Lozano JR, Nunez-Roldan A: Ctla4 polymorphisms in spanish patients with rheumatoid arthritis. Tissue Antigens 1999, 53:296-300.
• [12]Barton A, Myerscough A, John S, Gonzalez-Gay M, Ollier W, Worthington J: A single nucleotide polymorphism in exon 1 of cytotoxic t-lymphocyte-associated-4 (ctla-4) is not associated with rheumatoid arthritis. Rheumatology (Oxford) 2000, 39:63-66.
• [13]Yanagawa T, Gomi K, Nakao EI, Inada S: Ctla-4 gene polymorphism in japanese patients with rheumatoid arthritis. J Rheumatol 2000, 27:2740-2742.
• [14]Hadj Kacem H, Kaddour N, Adyel FZ, Bahloul Z, Ayadi H: Hla-dqb1 car1/car2, tnfa ir2/ir4 and ctla-4 polymorphisms in tunisian patients with rheumatoid arthritis and sjogren¿s syndrome. Rheumatology (Oxford) 2001, 40:1370-1374.
• [15]Milicic A, Brown MA, Wordsworth BP: Polymorphism in codon 17 of the ctla-4 gene (+49 a/g) is not associated with susceptibility to rheumatoid arthritis in british caucasians. Tissue Antigens 2001, 58:50-54.
• [16]Lee YH, Choi SJ, Ji JD, Song GG: No association of polymorphisms of the ctla-4 exon 1 (+49) and promoter (?318) genes with rheumatoid arthritis in the Korean population. Scand J Rheumatol 2002, 31:266-270.
• [17]Vaidya B, Pearce SHS, Charlton S, Marshall N, Rowan AD, Griffiths ID, Kendall-Taylor P, Cawston TE, Young-Min S: An association between the ctla4 exon 1 polymorphism and early rheumatoid arthritis with autoimmune endocrinopathies. Rheumatology 2002, 41:180-183.
• [18]Lee CS, Lee YJ, Liu HF, Su CH, Chang SC, Wang BR, Chen TL, Liu TL: Association of ctla4 gene a-g polymorphism with rheumatoid arthritis in chinese. Clin Rheumatol 2003, 22:221-224.
• [19]Liu MF, Wang CR, Chen PC, Lin TL: Ctla-4 gene polymorphism in promoter and exon-1 regions is not associated with chinese patients with rheumatoid arthritis. Clin Rheumatol 2004, 23:180-181.
• [20]Barton A, Jury F, Eyre S, Bowes J, Hinks A, Ward D, Worthington J: Haplotype analysis in simplex families and novel analytic approaches in a case¿control cohort reveal no evidence of association of the ctla-4 gene with rheumatoid arthritis. Arthritis Rheum 2004, 50:748-752.
• [21]Lei C, Dongqing Z, Yeqing S, Oaks MK, Lishan C, Jianzhong J, Jie Q, Fang D, Ningli L, Xinghai H, Daming R: Association of the ctla-4 gene with rheumatoid arthritis in chinese han population. Eur J Hum Genet 2005, 13:823-828.
• [22]Takeuchi F, Kawasugi K, Mori M, Nakaue N, Kobayashi N, Kuwata S, Murayama T, Matsuta K: The genetic contribution of ctla-4 dimorphisms in promoter and exon 1 regions in japanese patients with rheumatoid arthritis. Scand J Rheumatol 2006, 35:154-155.
• [23]Suppiah V, O¿Doherty C, Heggarty S, Patterson CC, Rooney M, Vandenbroeck K: The ctla4?+?49a/g and ct60 polymorphisms and chronic inflammatory arthropathies in northern ireland. Exp Mol Pathol 2006, 80:141-146.
• [24]Tsukahara S, Iwamoto T, Ikari K, Inoue E, Tomatsu T, Hara M, Yamanaka H, Kamatani N, Momohara S: Ctla-4 ct60 polymorphism is not an independent genetic risk marker of rheumatoid arthritis in a japanese population. Ann Rheum Dis 2008, 67:428-429.
• [25]Walker EJ, Hirschfield GM, Xu C, Lu Y, Liu X, Coltescu C, Wang K, Newman WG, Bykerk V, Keystone EC, Mosher D, Amos CI, Heathcote EJ, Siminovitch KA: Ctla4/icos gene variants and haplotypes are associated with rheumatoid arthritis and primary biliary cirrhosis in the canadian population. Arthritis Rheum 2009, 60:931-937.
• [26]Munoz-Valle JF, Valle Y, Padilla-Gutierrez JR, Parra-Rojas I, Rangel-Villalobos H, del Mercado MV, Ledezma-Lozano IY, Villafan-Bernal JR, Armendariz-Borunda J, Pereira-Suarez AL: The?+?49a?>?g ctla-4 polymorphism is associated with rheumatoid arthritis in mexican population. Clin Chim Acta 2010, 411:725-728.
• [27]Plant D, Flynn E, Mbarek H, Dieude P, Cornelis F, Arlestig L, Dahlqvist SR, Goulielmos G, Boumpas DT, Sidiropoulos P, Johansen JS, Ornbjerg LM, Hetland ML, Klareskog L, Filer A, Buckley CD, Raza K, Witte T, Schmidt RE, Worthington J: Investigation of potential non-hla rheumatoid arthritis susceptibility loci in a european cohort increases the evidence for nine markers. Ann Rheum Dis 2010, 69:1548-1553.
• [28]Benhatchi K, Jochmanova I, Habalova V, Wagnerova H, Lazurova I: Ctla4 exon1 a49g polymorphism in slovak patients with rheumatoid arthritis and hashimoto thyroiditis-results and the review of the literature. Clin Rheumatol 2011, 30:1319-1324.
• [29]Rocha MC, Santos LM, Bagatin E, Cohen Tervaert JW, Damoiseaux JG, Lido AV, Longhini AL, Torello CO, Queiroz ML: Genetic polymorphisms and surface expression of ctla-4 and pd-1 on t cells of silica-exposed workers. Int J Hyg Environ Health 2012, 215:562-569.
• [30]AlFadhli S: Overexpression and secretion of the soluble ctla-4 splice variant in various autoimmune diseases and in cases with overlapping autoimmunity. Genet Test Mol Biomarkers 2013, 17:336-341.
• [31]Shi Z, Cai L, Han X, Zhang D, Chen L, Jin J, Qian J, Du F, Ren D: Association between ctla-4 polymorphism and rheumatoid arthritis in Chinese. Zhonghua Fengshixue Zazhi 2007, 11:78-81.
• [32]Tang MJ, Zhou ZB: Association of the ctla-4?+?49a/g polymorphism with rheumatoid arthritis in chinese han population. Mol Biol Rep 2013, 40:2627-2631.
• [33]Liu CP, Jiang JA, Wang T, Liu XM, Gao L, Zhu RR, Shen Y, Wu M, Xu T, Zhang XG: Ctla-4 and cd86 genetic variants and haplotypes in patients with rheumatoid arthritis in southeastern china. Genet Mol Res 2013, 12:1373-1382.
• [34]Zeng Z, Duan Z, Zhang T, Wang S, Li G, Gao J, Ye D, Xu S, Xu J, Zhang L, Pan F: Association between tumor necrosis factor-alpha (tnf-alpha) promoter ?308 g/a and response to tnf-alpha blockers in rheumatoid arthritis: a meta-analysis. Mod Rheumatol 2013, 23:489-495.
• [35]Schott E, Witt H, Pascu M, van Boemmel F, Weich V, Bergk A, Halangk J, Muller T, Puhl G, Wiedenmann B, Berg T: Association of ctla4 single nucleotide polymorphisms with viral but not autoimmune liver disease. Eur J Gastroenterol Hepatol 2007, 19:947-951.
• [36]Joshita S, Umemura T, Yoshizawa K, Katsuyama Y, Tanaka E, Nakamura M, Ishibashi H, Ota M: Association analysis of cytotoxic t-lymphocyte antigen 4 gene polymorphisms with primary biliary cirrhosis in japanese patients. J Hepatol 2010, 53:537-541.
• [37]Lee YH, Bae SC, Choi SJ, Ji JD, Song GG: Association between the ctla-4?+?49 a/g polymorphism and susceptibility to rheumatoid arthritis: A meta-analysis. Mol Biol Rep 2012, 39:5599-5605.
• [38]Li X, Zhang C, Zhang J, Zhang Y, Wu Z, Yang L, Xiang Z, Qi Z, Zhang X, Xiao X: Polymorphisms in the ctla-4 gene and rheumatoid arthritis susceptibility: a meta-analysis. J Clin Immunol 2012, 32:530-539.
• [39]Dai D, Chen Y, Ru P, Zhou X, Tao J, Ye H, Hong Q, Tang L, Pan G, Lin D, Gong Q, Lv Y, Xu L, Duan S: Significant association between tap2 polymorphisms and rheumatoid arthritis: a meta-analysis. Diagn Pathol 2014, 9:129. BioMed Central Full Text
• [40]Kumar Y, Bhatia A, Minz RW: Antinuclear antibodies and their detection methods in diagnosis of connective tissue diseases: a journey revisited. Diagn Pathol 2009, 4:1. BioMed Central Full Text